Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Advanced Neuromuscular Medicine Fellowship, Duke University School of Medicine 2016 - 2017
  • Neuromuscular Medicine Fellowship, Neurology, Duke University School of Medicine 2015 - 2016
  • Neurology Residency, Adult Neurology, University of Maryland School of Medicine 2012 - 2015
  • Internship, Medicine, University of Maryland School of Medicine 2011 - 2012
  • M.D., Thomas Jefferson University 2011
• Research
• 

  Selected Grants

  • AANEM Autoimmune Neuromuscular Disorders Fellowship awarded by AANEM Foundation for Research & Education 2017 - 2018
• Publications & Artistic Works
• 

  Selected Publications

  • Journal Articles

    • Guptill JT, Raja S, Sanders DB, Narayanaswami P. Comparative effectiveness clinical trials to advance treatment of myasthenia gravis. Annals of the New York Academy of Sciences. 2018 Feb;1413(1):69-75. PubMed PMID: 29377158. (Review)  Full Text
    • Sanders DB, Guptill JT, Aleš KL, Hobson-Webb LD, Jacobus DP, Mahmood R, Massey JM, Pittman MM, Prather K, Raja SM, Yow E, Juel VC. Reliability of the triple-timed up-and-go test. Muscle & nerve. 2018 Jan;57(1):136-139. PubMed PMID: 28545168.  Full Text
    • Guptill JT, Raja SM, Boakye-Agyeman F, Noveck R, Ramey S, Tu TM, Laskowitz DT. Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects. Journal of clinical pharmacology. 2017 Jun;57(6):770-776. PubMed PMID: 27990643.  Full Text
    • Yi JS, Russo MA, Massey JM, Juel V, Hobson-Webb LD, Gable K, Raja SM, Balderson K, Weinhold KJ, Guptill JT. B10 Cell Frequencies and Suppressive Capacity in Myasthenia Gravis Are Associated with Disease Severity. Frontiers in Neurology. 2017 Jan;8:34-. PubMed PMID: 28239367.  Full Text  Open Access Copy
    • Chen S, Fu L, Raja SM, Yue P, Peterson YK, Khuri FR, Sun S-Y. Differential roles of DR4, DR5 and c-FLIP in regulation of geranylgeranyltransferase I inhibitor-induced augmentation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. CANCER RESEARCH. 2009 May 1;69.  Link to Item
    • Raja SM, Chen S, Yue P, Acker TM, Lefkove B, Arbiser JL, Khuri FR, Sun S-Y. The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Molecular Cancer Therapeutics. 2008 Jul 1;7(7):2212-2223.  Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.